Why Our Speakers Are Excited:

"The field of RNA editing has been exploding the last couple of years, and this inaugural RNA editing summit is going to be a great place for people to hear the science about RNA editors, as well as the different approaches to utilize or inhibit these enzymes for the treatment of human diseases."

Scott Ribich, Vice President, Biology, Accent Therapeutics


"RNA editing expands the evolutionary landscape by increasing the diversity of gene products and enhances the therapeutic universe by enabling interventions that go beyond what is possible in a world focused solely on rewriting DNA sequence. This meeting will help expand the collaborations and toolsets for this new era of innovation."

Alan Herbert, Founder & Head of Discovery, InsideOutBio

"RNA editing is an exciting new tool in the genome engineering toolbox with distinct advantages over DNA editing and I’m excited to see the latest and greatest developments in the field at the meeting."

Omar Abudayyeh, McGovern Fellow, the McGovern Institute for Brain Research, MIT

"RNA editing is a rapidly growing field, and I'm excited to see what is presented at the summit."

Jonathan Gootenberg, McGovern Fellow, the McGovern Institute for Brain Research, MIT

"All of us were taught that transcript RNA should match in sequence the gene that encodes it. Enter editing, which is robust, reproducible, targetable, functionally critical - it's clearly time to update the books! For someone who's been having fun with RNA editing for the last 10+ years, it's exciting to see it hit the limelight, and attract such basic as well as translational interest. I’m very much looking forward to sharing insights with aficionados old and new at what promises to be a fantastic meeting."

Nina Papavasiliou, University Professor and Division Head, German Cancer Research Center, Heidelberg, Germany, and Visiting Professor, Rockefeller University, New York

"Having studied RNA editing for over 10 years, I am fortunate to witness the growth of the RNA editing field from basic research to multiple avenues of therapeutic applications."

Jin Billy Li, Associate Professor, Stanford University